CPA7 is a novel Stat3 inhibitor. CPA7 downregulates survivin, Bcl-XL, and Mcl-1. CPA7 induces Apoptosis. CPA7 enhances the radiosensitivity of prostate cancer. CPA7 has anti-cancer effects against prostate cancer[1][2].
Molecular Weight:
381.51
CAS Number:
[16961-77-6]
Formula:
Cl3H6N3O2Pt
Target:
Apoptosis,Bcl-2 Family,STAT,Survivin
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted